. Flowchart for the ZOE-50 study * Each dimension is scored on a scale from 0 to 100 with 100 signifying optimal functioning.
Summary scores for the physical component score (PCS) and the mental component score (MCS) were also calculated [1] .
The comparisons of the SF-36 QoL measures between the RZV and placebo groups showed in both analyses a trend towards higher QoL scores in the RZV groups than in the placebo groups. Very few of the multiple comparisons identified statistically significant differences, however. For illustration, the values observed at Week 1 with the highest completion rate are shown in Table S2 . 
ZOE-70 Analysis
The mean delay between the date of rash onset and the first HZ evaluation was 4.6 days (range 0-33). Completion rates for the Zoster Brief Pain Inventory (ZBPI) questionnaire were approximately 15% on Day 0, >60% from Day 3 onwards and ≥80% from Day 6 onwards.
For the EQ-5D and SF-36 instruments during an ongoing HZ episode, the completion rates were approximately 52% on Day 0 and ≥83% at all time points thereafter.
The estimated overall VE in reducing the ZBPI burden of illness and burden of interference were 90.5% and 88.2%, respectively (Table S3 ). A severe ZBPI 'worst-pain' score (i.e., ≥7) was reported by 42.9% in the RZV group and 66.8% in the placebo group (VE 35.9%, 95%CI 3.5% to 63.7%, Table S4 ). The corresponding proportions reporting severe ZBPI 'average pain' were 23.8 and 41.8%, respectively (VE 43.1%, 95%CI -10.8% to 75.0%). The median time to resolution of clinically significant pain (i.e., ZBPI 'worst pain' ≥3) was 14 days in the RZV group and 22 days in the placebo group (p = .635). Table S5 presents the utility loss of the HZ patients in the placebo groups over the first 28 days after rash onset, assessed using the EQ-5D instrument. The estimated utility loss was highest on Day 0 and decreased over time in all age groups as the patients recovered from HZ but a negative impact of HZ on QoL remained until the end of Week 4. The estimated differences over time in mean EQ-5D utility scores between the RZV and placebo groups are presented in Figure S4 . 
